Model SENTI-401 -Colorectal Cancer (CRC) Cells
Pursuing an Unmet Need in the Treatment of CRC - SENTI-401 is designed to more precisely target and eliminate colorectal cancer (CRC) cells while sparing healthy cells elsewhere in the body. Our vision is a potential medicine that more effectively treats patients with colorectal cancer.
Most popular related searches
colorectal cancer
colorectal cancer cell
natural killer cell therapy
cancer cell
natural killer cell
cell therapy
cancer antigen
antigen associated
allogeneic cell
Logic Gated Allogeneic CAR-NK Cell Therapy for CRC
The product profile of SENTI-401 has the potential to target a well-known tumor associated antigen, carcinoembryonic antigen (CEA), and widen the therapeutic window by preventing killing when CEA appears on healthy cells that also expresses an epithelial cell Safety Antigen.